Who are GC FLU Quadrivalent's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Agriflu (TIV), Trivalent Influenza Vaccine, CSL Limited Influenza Vaccine, Fluval AB vaccination, Enzira® vaccine, Anti-pandemic H1N1 influenza vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gc-flu-quadrivalent.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

GC FLU Quadrivalent — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GC FLU Quadrivalent (GC FLU Quadrivalent) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated influenza vaccine. Area: Immunology / Infectious Disease.

phase 3 Inactivated influenza vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

GC FLU Quadrivalent (GC FLU Quadrivalent) — Medigen Vaccine Biologics Corp.. GC FLU Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
GC FLU Quadrivalent TARGET	GC FLU Quadrivalent	Medigen Vaccine Biologics Corp.	phase 3	Inactivated influenza vaccine
Agriflu (TIV)	Agriflu (TIV)	Novartis	marketed	Inactivated influenza vaccine
Trivalent Influenza Vaccine	Trivalent Influenza Vaccine	MedImmune LLC	marketed	Inactivated influenza vaccine
CSL Limited Influenza Vaccine	CSL Limited Influenza Vaccine	Seqirus	marketed	inactivated influenza vaccine
Fluval AB vaccination	Fluval AB vaccination	Fluart Innovative Vaccine Ltd, Hungary	marketed	Inactivated influenza vaccine
Enzira® vaccine	Enzira® vaccine	Seqirus	marketed	Inactivated influenza vaccine
Anti-pandemic H1N1 influenza vaccine	Anti-pandemic H1N1 influenza vaccine	University of Sao Paulo	marketed	inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated influenza vaccine class)

GlaxoSmithKline · 16 drugs in this class
Seqirus · 5 drugs in this class
Sanofi Pasteur, a Sanofi Company · 5 drugs in this class
Green Cross Corporation · 4 drugs in this class
Novartis · 2 drugs in this class
SK Chemicals Co., Ltd. · 2 drugs in this class
Sanofi · 2 drugs in this class
Hospital Israelita Albert Einstein · 2 drugs in this class
McGill University Health Centre/Research Institute of the McGill University Health Centre · 2 drugs in this class
Il-Yang Pharm. Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GC FLU Quadrivalent — Competitive Intelligence Brief. https://druglandscape.com/ci/gc-flu-quadrivalent. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing